A Study to Evaluate the Efficacy and Safety of AD-223

Phase 3CompletedNCT06052748

Addpharma Inc.502 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-223

Condition or disease : hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

502

Conditions

Hypertension,Essential

Interventions

AD-223ADRUG

PO, Once daily(QD), 8weeks

AD-223BDRUG

PO, Once daily(QD), 8weeks

AD-223CDRUG

PO, Once daily(QD), 8weeks

AD-223A Placebo

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Other inclusions applied Exclusion Criteria: * Orthostatic hypotension with symptom * Other exclusions applied

Locations (1)

Hanyang University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Change rate of MSSBP

Change from baseline in mean sitting systolic blood pressure

Time frame: Baseline, Week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.